Trial Review

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this information for consumers
Trial details imported from ClinicalTrials.gov

For full trial details, please see the original record at https://clinicaltrials.gov/ct2/show/NCT03302728




Registration number
NCT03302728
Ethics application status
Date submitted
1/10/2017
Date registered
5/10/2017
Date last updated
19/05/2022

Titles & IDs
Public title
Brentuximab Vedotin and Lenalidomide in Patients With Relapsed/ Refractory T-cell Lymphoma or Hodgkin Lymphoma
Scientific title
A Phase 1b Study of Brentuximab Vedotin and Lenalidomide in Patients With Relapsed/ Refractory Cutaneous T-cell Lymphoma, CD30-positive Peripheral T-cell Lymphoma, or CD30-positive Hodgkin Lymphoma
Secondary ID [1] 0 0
17/34
Universal Trial Number (UTN)
Trial acronym
EpiBrentlen
Linked study record

Health condition
Health condition(s) or problem(s) studied:
Lymphoma, T-Cell, Cutaneous 0 0
Lymphoma, T-Cell, Peripheral 0 0
Hodgkin Lymphoma 0 0
Condition category
Condition code
Cancer 0 0 0 0
Lymphoma (non Hodgkin's lymphoma) - High grade lymphoma
Cancer 0 0 0 0
Lymphoma (non Hodgkin's lymphoma) - Low grade lymphoma
Cancer 0 0 0 0
Hodgkin's

Intervention/exposure
Study type
Interventional
Description of intervention(s) / exposure
Treatment: Drugs - Lenalidomide 15mg
Treatment: Drugs - Brentuximab Vedotin 1.8 mg/Kg

Experimental: Lenalidomide & brentuximab vedotin - Brentuximab vedotin 1.8mg/Kg Lenalidomide 15 mg


Treatment: Drugs: Lenalidomide 15mg
At commencement of study : Lenalidomide will commence at 15 mg daily for days 1-14 of each cycle. Maximum number of cycles = 16. This is a dose finding study so doses will be adjusted depending on toxicity assessment over the course of the study. Dose may vary from 5 mg -25 mg daily depending on dose escalation results and recommendation of safety committee

Treatment: Drugs: Brentuximab Vedotin 1.8 mg/Kg
At commencement of study : Brentuximab vedotin 1.8mg/kg IV on day 1, repeated every 21 days. Maximum number of cycles = 16. This is a dose finding study so doses will be adjusted depending on toxicity assessment over the course of the study. Dose may be either 1.2 mg/Kg q21 days or 1.8 mg/kg q21 days depending on dose escalation results and recommendation of safety committee
Intervention code [1] 0 0
Treatment: Drugs
Comparator / control treatment
Control group

Outcomes
Primary outcome [1] 0 0
Determination of the maximum tolerated dose (MTD), dose-limiting toxicities (DLTs), and recommended phase 2 dose (RP2D) of the combination of lenalidomide and brentuximab vedotin
Timepoint [1] 0 0
70 weeks
Secondary outcome [1] 0 0
Safety profile of the combination of lenalidomide and brentuximab vedotin
Timepoint [1] 0 0
70 weeks
Secondary outcome [2] 0 0
Treatment intensity.
Timepoint [2] 0 0
48 weeks
Secondary outcome [3] 0 0
Objective response rate
Timepoint [3] 0 0
70 weeks
Secondary outcome [4] 0 0
Cytostatic response.
Timepoint [4] 0 0
70 weeks
Secondary outcome [5] 0 0
Event free survival.
Timepoint [5] 0 0
70 weeks
Secondary outcome [6] 0 0
Overall survival
Timepoint [6] 0 0
70 weeks

Eligibility
Key inclusion criteria
1. Male or female patients of 18 years or older.

2. Patient must have a diagnosis of a CD30+ Hodgkin Lymphoma or CD30+ peripheral T-cell
lymphoma. Patients with either Hodgkin lymphoma or T-cell lymphoma must have
expression of CD30 in =10% of lymphoma cells. Patients with CTCL will be considered
for inclusion even if CD30 immunohistochemical staining with BerH2 antibody is low or
negligible (<10%).

1. Peripheral T-cell lymphoma: patients must be considered relapsed or refractory
after at least one prior chemotherapeutic regimen or be considered by the
investigator to be not suitable for chemotherapy

2. Cutaneous T-cell lymphoma: patients must be relapsed or refractory to one prior
systemic therapy or be considered by the investigator to be not suitable for
chemotherapy

3. Patients with Hodgkin lymphoma and one of the following:

i. Relapsed or refractory after at least 2 prior chemotherapy-containing regimens
ii.Considered unsuitable for chemotherapy

3. Voluntary written informed consent must be given before performance of any study-
related procedure.

4. Female patient is either post-menopausal for at least 1 year before the screening
visit or surgically sterile or if of childbearing potential, agree to practice 2
effective methods of contraception, at the same time, from the time of signing the
informed consent through 6 months after the last dose of study drug, or agrees to
completely abstain from heterosexual intercourse.

5. Male patients, even if surgically sterilized, (i.e., status post vasectomy) agree to
practice effective barrier contraception during the entire study period and through 6
months after the last dose of study drug, or agrees to completely abstain from
heterosexual intercourse.

6. Performance status of ECOG =2.

7. Clinical laboratory values as specified below. Blood tests must be within 10 days of
patient registration:

- Absolute neutrophil count >1.5 x109/L, or >1.0 x109/L in the setting of known
marrow involvement by tumour.

- Platelet count =75x109/L.

- Total bilirubin must be < 1.5 x the upper limit of the normal (ULN) unless the
elevation is known to be due to Gilbert syndrome.

- ALT or AST must be < 2.5 x the upper limit of the normal range. AST or ALT may be
elevated up to 5 times the ULN if their elevation can be reasonably ascribed to
the presence of haematologic/solid tumor in liver.

- Serum creatinine must be < 150 µmol/L and/or creatinine clearance or calculated
creatinine clearance > 40 mL/minute.

- Haemoglobin must be = 80g/L.

8. Patients must have fully recovered from the acute toxic effects of all prior
chemotherapy, immunotherapy, or radiotherapy (except alopecia) prior to registration.
Minimum age
18 Years
Maximum age
No limit
Sex
Both males and females
Can healthy volunteers participate?
No
Key exclusion criteria
1. Female patients who are both lactating and breast-feeding or have a positive serum
pregnancy test during the screening period or a positive pregnancy test on planned
cycle 1, day 1 prior to first dose of study drug.

2. Any serious medical or psychiatric illness that could, in the investigator's opinion,
potentially interfere with the completion of treatment according to the protocol.

3. Symptomatic neurologic disease compromising normal activities of daily living or
requiring medication/s, including signs or symptoms of Progressive Multifocal
Leucoencephalopathy (PML).

4. Any sensory or motor peripheral neuropathy greater than or equal to Grade 2 at
registration.

5. Known history of any of the following cardiovascular conditions

1. New York Heart Association (NYHA) Class III or IV heart failure (see Appendix
18.1).

2. Evidence of current uncontrolled cardiovascular conditions, including cardiac
arrhythmias, congestive heart failure (CHF), angina, or electrocardiographic
evidence of acute ischemia or active conduction system abnormalities.

3. A left-ventricular ejection fraction <50%

6. Any active systemic viral, bacterial, or fungal infection requiring systemic
intravenous antibiotics or systemic antifungal therapies within 2 weeks prior to
registration.

7. Patients that have not completed any prior treatment chemotherapy and/or other
investigational agents within at least 5 half-lives of last dose of that prior
treatment.

8. Known hypersensitivity to recombinant proteins, murine proteins, or to any excipient
contained in the drug formulation of brentuximab vedotin or lenalidomide.

9. Known human immunodeficiency virus (HIV) positive.

10. Known hepatitis B surface antigen (HBsAg)-positive, or known or suspected active
hepatitis C infection. Patients who are Hepatitis B core antibody positive with no
evidence of active disease, i.e.

HBsAg negative/ negative hepatitis B viral load, will still be considered eligible for
inclusion, but must receive viral suppressive therapy for the duration of the trial.

11. Active systemic malignancy likely to require treatment within the next two years, or
previous diagnosis of another malignancy with residual disease. Patients with
non-melanoma skin cancer or carcinoma- in-situ of any type are not excluded if they
have undergone complete resection.

12. Previous exposure to brentuximab vedotin.

Study design
Purpose of the study
Treatment
Allocation to intervention
N/A
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Masking / blinding
Open (masking not used)
Who is / are masked / blinded?



Intervention assignment
Single group
Other design features
Phase
Phase 1
Type of endpoint/s
Statistical methods / analysis

Recruitment
Recruitment status
Completed
Data analysis
Reason for early stopping/withdrawal
Other reasons
Date of first participant enrolment
Anticipated
Actual
30/08/2018
Date of last participant enrolment
Anticipated
Actual
Date of last data collection
Anticipated
Actual
2/08/2021
Sample size
Target
Accrual to date
Final
6
Recruitment in Australia
Recruitment state(s)
VIC
Recruitment hospital [1] 0 0
Peter MacCallum Cancer Centre - Melbourne
Recruitment postcode(s) [1] 0 0
3000 - Melbourne

Funding & Sponsors
Primary sponsor type
Other
Name
Peter MacCallum Cancer Centre, Australia
Address
Country

Ethics approval
Ethics application status

Summary
Brief summary
This study is investigating the combination of Brentuximab vedotin and lenalidomide in the
treatment of relapsed/refractory peripheral T cell lymphoma or cutaneous T cell lymphoma or
Hodgkin lymphoma.

It is hypothesised that lenalidomide may augment the actions of Brentuximab vedotin in these
patient groups. The primary objective of the study is to determine the maximum tolerated dose
of the combination treatment, which can be used in subsequent studies. The study will also
investigate disease response and survival.

Participants will receive Brentuximab vedotin (once every 21 days i.e. 1 cycle) and
lenalidomide (daily from day 1 -14 of each cycle) for a maximum of 48 weeks and will be
followed for a subsequent 6 months after the end of treatment.
Trial website
https://clinicaltrials.gov/ct2/show/NCT03302728
Trial related presentations / publications
Public notes

Contacts
Principal investigator
Name 0 0
Michael Dickinson, Dr
Address 0 0
Peter MacCallum Cancer Centre, Australia
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for public queries
Name 0 0
Address 0 0
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for scientific queries



Summary Results

For IPD and results data, please see https://clinicaltrials.gov/ct2/show/NCT03302728